Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine

American Journal of Obstetrics and Gynecology

Volumn 187, Issue 6, 2002, Pages 1555-1560

  Zoma, Willie D ^a   Baker, R Scott ^a   Kopernik, Gideon ^a   Mershon, John L ^a   Clark, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Blood flow; Breast; Estrogen; Selective estrogen receptor modulator; Sheep

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HEMODYNAMIC MONITORING; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE SUBSTITUTION; NONHUMAN; PRIORITY JOURNAL; SHEEP; STATISTICAL SIGNIFICANCE; TISSUE BLOOD FLOW; UTERUS BLOOD FLOW;

EID: 0036910215     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.127600     Document Type: Article

References (25)

1. Writing Group of PEPI Trial effects of hormone therapy on bone mineral density. JAMA 1996;276:1389-96.
2. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen and coronary heart disease. N Engl J Med 1985;313:1044-9.
3. Rozenberg S, Vandromme J, Knoll M, et al. Compliance to hormone replacement therapy. Int J Fertil Menopausal Stud 1995;40(Suppl):23-32.
4. Stomper PC, Van Voorhis BJ, Ravnikar VA, et al. Mammographic changes associated with postmenopausal hormone replacement therapy: A longitudinal study. Radiology, 1990;174:487-90.
5. Laya MB, Gallagher JC, Schreiman JS, et al. Effects of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
6. Laya MB, Larson EB, Taplin SH, et al. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643-9.
7. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial: Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34.
8. Son HJ, Oh KK. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999;173:905-9.
9. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen or placebo. J Natl Cancer Inst 2001;93:51-6.
10. Erel CT, Elter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870-5.
11. Rosenfeld C, Killam AP, Battaglia FC, et al. Effects of estradiol-17β on the magnitude and distribution of uterine blood flow in non-pregnant, oophorectomized ewe. Pediatr Res 1973;7:139-48.
12. Burd LI, Lemons JA, Makowski EL, et al. Relationship of mammary blood flow to parturition in the ewe. Am J Physiol 1975;229:797-800.
13. Clark KE, Baker RS, Lang U. Premarin-induced increases in coronary and uterine blood flow in nonpregnant sheep. Am J Obstet Gynecol 2000;183:12-7.
14. Zoma WD, Lang U, Baker RS, et al. Hemodynamic response to tibolone in reproductive and nonreproductive tissues in the sheep. Am J Obstet Gynecol 2001;184:544-51.
15. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 2000;182:521-8.
16. Hsueh AJW, Peck EJ, Clark JH. Progesterone antagonism of oestrogen receptor and oestrogen-induced uterine growth. Nature 1975;254:337-9.
17. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidene, or estrogen effects on reproductive and non-reproductive tissues in ovariectomized aged rats. FASEB J 1996;10:905-12.
18. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-535.
19. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
20. Chao T, Lo Y, Chen S, et al. Color Doppler ultrasound in benign and malignant breast tumors. Breast Cancer Res Treat 1999;57:193-9.
21. Holcombe C, Pugh N, Lyons K, et al. Blood flow in breast cancer and fibroadenoma estimated by color Doppler ultrasonography. Br J Surg 1995;82:787-8.
22. Nechmad A, Merin G, Schwalb H, et al. Estrogen induces nitric oxide-mediated vasodilation of human mammary arteries in vitro. Nitric Oxide 1998;2:460-6.
23. Cohen FJ, Watts S, Shah A, et al. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-10.
24. McNicholas MMJ, Heneghan JP, Milner MH, et al. Pain and increased mammographic density in women receiving hormone replacement therapy: A prospective study. AJR Am J Roentgenol 1994;163:311-5.
25. Harvey JA, Inkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 1997;89:1623-5.